
Opiant Pharmaceuticals OPNT
Quarterly report 2022-Q3
added 11-14-2022
Opiant Pharmaceuticals DPO Ratio 2011-2026 | OPNT
Annual DPO Ratio Opiant Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 175 | 62.3 | 277 | - | - | - | - | - | 11.1 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 277 | 11.1 | 131 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
55 | $ 322.18 | -3.36 % | $ 42.2 B | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 22.0 | 1.48 % | $ 1.03 B | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
1.83 K | - | -5.16 % | $ 5.39 M | ||
|
Akebia Therapeutics
AKBA
|
168 | $ 1.38 | -10.97 % | $ 355 M | ||
|
Aquestive Therapeutics
AQST
|
395 | $ 4.28 | 0.94 % | $ 458 M | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.69 | -3.64 % | $ 3.01 B | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.59 | 6.71 % | $ 423 M | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Caladrius Biosciences
CLBS
|
51.2 | - | -16.75 % | $ 25.8 M | ||
|
Clearside Biomedical
CLSD
|
1.67 K | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
4.06 K | $ 33.63 | -0.72 % | $ 2.23 B |